In this PDX study, concurrent EGFR and RAF inhibition demonstrated synergistic antitumor activity for CRC PDX models with a KRAS or BRAF mutation, providing a potential treatment option in a clinical trial setting for CRC patients with KRAS- or BRAF-mutant tumors. Here, BRAF is linked to colorectal carcinoma.